Título del libro: Translational Autoimmunity: Autoimmune Diseases In Different Organs
Título del capítulo: Pathogenesis-based treatments in bullous pemphigoid
JOSE ALEXANDRO BONIFAZ TRUJILLO;
Autores externos:
Idioma:
Año de publicación:
2022
Palabras clave:
Autoantibodies; Autoimmune; Corticosteroids; Glucocorticoids; Immunosuppressant; Pemphigoid
Resumen:
Pemphigoid is one of the most common autoimmune bullous diseases in the elderly, characterized by subepidermal blisters due to autoantibodies against the adhesion proteins of hemidesmosomes (BP180/collagen type XVII and BP230/dystonin-e). It usually affects patients over 70years of age, causing tense mucocutaneous blisters. The disease generally shows a chronic and recurrent often recalcitrant course, usually requiring long-term corticosteroid use, alone or in combination with systemic immunosuppressants (called steroid-sparing agents). At present, there is no curative treatment, and current alternatives may trigger adverse events, thus increasing mortality rates; therefore, it is necessary to develop pathogenesis-based therapies with fewer side effects. The treatment of choice for bullous pemphigoid mainly depends on disease activity. Class I topical corticosteroids, including clobetasol propionate, are often used in mild-to-moderate disease, whereas in cases of extensive or refractory disease, the selected therapy usually includes systemic steroids alone or in combination with other immunosuppressants, providing a steroid-sparing effect. New treatments such as rituximab, intravenous immunoglobulin, and omalizumab are promising options; however, their use is limited due to the high cost. In this review, we will address the status of bullous pemphigoid therapy and the most used treatments in dermatological practice. © 2022 Elsevier Inc. All rights reserved.
Entidades citadas de la UNAM:
ISBN:
9780128244661
Editorial:
Elsevier Nombre de la publicación:
Pathogenesis-based treatments in bullous pemphigoid
Página inicial:
373
Página final:
387
